By John Vandermosten, CFANASDAQ:ACHVREAD THE FULL ACHV RESEARCH REPORTINITIATING COVERAGEAchieve Life Sciences, Inc. (NASDAQ:ACHV) is developing cytisinicline, historically known as cytisine, for nicotine addiction. The drug is currently available over the counter (OTC) in several eastern European countries for this indication and has been successful with annual revenues in...
By John Vandermosten, CFANASDAQ:HTBXHeat Biologics, Inc. (NASDAQ:HTBX) has continued to progress in their HS-110 Durga trial, recently providing interim results at the ASCO-SITC Clinical Immuno-Oncology Symposium. The Phase II study is evaluating HS-110 in conjunction with checkpoint inhibitors for patients in non-small cell lung cancer (NSCLC) who have failed...
By Brian Marckx, CFAOTC:SMLRREAD THE FULL SMLR RESEARCH REPORTQ4 2018 Results: Revenue, Earnings & Cash Flow Continue to Climb. Cash Flow Forecast Implies $45/Share Fair Value…Semler (OTC:SMLR) reported financial results for the fourth quarter ending December 31, 2018. While revenue slightly missed our estimate, it nonetheless came in strong...
While using artificial intelligence and machine learning to optimize health care isn’t a novel concept, KenSci proclaims its mission is more broadly to fight death with data science. By collecting big data, analyzing variables and outcomes, and suggesting cost-effective and successful solutions, KenSci is aiding medical professionals in fending...
By David Bautz, PhDTSX:ATE.VREAD THE FULL ATE.V RESEARCH REPORTFinancial UpdateOn February 15, 2019, Antibe Therapeutics, Inc. (TSX:ATE.V) announced financial results for the third quarter of fiscal year 2019 ending Dec. 31, 2018. The company reported CAD$2.5 million in revenue for the three months ending Dec. 31, 2018 compared to...
By David Bautz, PhDNASDAQ:MTFBREAD THE FULL MTFB RESEARCH REPORTBusiness UpdateCRL for IclaprimOn February 14, 2019, Motif Bio Plc (NASDAQ:MTFB) announced that the U.S. FDA issued a complete response letter (CRL) for the new drug application (NDA) for the company’s lead asset iclaprim for the treatment of acute bacterial skin...
By David Bautz, PhDNASDAQ:MNOVREAD THE FULL MNOV RESEARCH REPORTBusiness UpdateAdvancing MN-166 to Phase 3 for Progressive MS and ALSMediciNova, Inc. (NASDAQ:MNOV) is currently developing MN-166 (ibudilast) for a number of indications, with the lead programs being in progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The company has...
By Steven Ralston, CFATSX:WML.VOTC:WMLLFREAD THE FULL RESEARCH REPORT HEREWealth Minerals (TSX:WML.V) (OTC:WMLLF) is a junior mineral exploration company that is well-positioned to benefit from its portfolio of prospective lithium projects in the Lithium Triangle. The company holds control over portions of several lithium salar projects in northern Chile (Atacama,...
By David Bautz, PhDREAD THE FULL RESEARCH REPORT HERENASDAQ:SNGXBusiness UpdateInnate Defense Regulators Offer Novel Means to Treat InfectionsSoligenix, Inc. (NASDAQ:SNGX) recently published a review of the potential clinical applications for innate defense regulators (IDRs), including the company’s lead IDR asset SGX942. IDRs modulate the innate immune response, which is...
By David Bautz, PhDNASDAQ:AGRXREAD THE FULL RESEARCH REPORT HEREBusiness UpdateAdhesion Study SuccessfulOn February 11, 2019, Agile Therapeutics, Inc. (NASDAQ:AGRX) announced positive topline results for the comparative adhesion study that tested the company’s investigational low-dose once-weekly contraceptive patch (Twirla®) against Xulane®, the generic version of the contraceptive patch Ortho Evra®....